ArticleClinical kidney journal2025
Global, regional and national epidemiology of anemia attributable to chronic kidney disease, 1990-2021.
Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy and safety of prolyl hydroxylase inhibitors for anemia in chronic kidney disease: a network meta-analysis.Renal failure · 2026Article
- KDIGO 2026 Clinical Practice Guideline for Anemia in Chronic Kidney Disease (CKD): a commentary from the European Renal Best Practice (ERBP).Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic kidney disease (CKD) presents a significant global health challenge, with anemia frequently manifesting in the more advanced stages. This study aimed to evaluate the global burden and cross-country inequality of CKD-related anemia from 1990 to 2021. Methods: Data on CKD-related anemia were extracted from the Global Burden of Disease 2021 study. Trends in prevalence, years lived with disability (YLDs) and corresponding estimated annual percentage changes (EAPCs) from 1990 to 2021 were analyzed at global, regional and national levels. Health inequity analysis methodologies were employed to evaluate cross-country inequality based on sociodemographic index. Results: In 2021, global CKD-related anemia cases reached 63 751 624 [95% uncertainty interval (UI), 59 045 051-68 372 650], representing a 96.24% increase from 1990 (32 486 224; 95% UI 30 356 876-35 047 084). Notwithstanding this increase, global prevalence [EAPC -0.27; 95% confidence interval (CI) -0.34 to -0.21] and YLDs rates (EAPC -0.66; 95% CI -0.70 to -0.62) generally declined. Females were disproportionately affected, comprising 55.75% of prevalence cases and 65.87% of YLDs numbers in 2021. From 1990 to 2021, the burden increased in individuals with CKD-related anemia associated with type 1 diabetes. Significant cross-country inequalities in prevalence were observed and persisted [slope index of inequality: 255.04 (389.56-120.51) in 1990 to 423.30 (572.78-273.81) in 2021; health concentration index: -0.09 (-0.12 to -0.07) in 1990 to -0.14 (-0.17 to -0.11) in 2021]. Conclusions: Despite the global decline in prevalence and YLDs rates of CKD-related anemia, the number of cases continued to increase, and the burden disproportionately concentrated in less developed countries and territories. This investigation also revealed a gender disparity and the influence of specific causes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.